Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK2 | Q92630 | 18/20 | 0.73 |
| ▸ | PIM1 | P11309 | 2/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26447967 | 1.00 | DYRK2 (0.73) | DYRK2PIM1CDK6 | |
| SCHEMBL30569700 | 0.92 | DYRK2 (0.83) | DYRK2PIM1CDK6 | |
| SCHEMBL26447994 | 0.92 | DYRK2 (0.83) | DYRK2PIM1CDK6 | |
| SCHEMBL26447956 | 0.91 | DYRK2 (0.87) | DYRK2CDK6 | |
| SCHEMBL30569703 | 0.91 | DYRK2 (0.87) | DYRK2CDK6 | |
| SCHEMBL32677354 | 0.89 | DYRK2 (0.73) | DYRK2CDK6 | |
| SCHEMBL26447949 | 0.89 | DYRK2 (0.73) | DYRK2CDK6 | |
| SCHEMBL30569706 | 0.87 | DYRK2 (0.81) | DYRK2PIM1CDK6 | |
| SCHEMBL26447886 | 0.87 | DYRK2 (0.81) | DYRK2PIM1CDK6 | |
| SCHEMBL30569711 | 0.86 | DYRK2 (0.83) | DYRK2CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559485-B2 | CDK6/DYRK2 dual-target inhibitor, and preparation method therefor and use thereof | JIANGSU TASLY DIYI PHARMACEUTICAL CO. , LTD. (CN) | 2026-02-24 | — | — | US | disclosed |
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CDK6, DYRK2, CDK16 | DYRK2 2/4885PIM1 393/4885CDK6 1/4885 |
| US-12559485-B2 | CDK6/DYRK2 dual-target inhibitor, and preparation method therefor and use thereof | CDK6, CDK2, CDKL1 | DYRK2 23/4885PIM1 92/4885CDK6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.